|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Extrahepatic Bile Duct Cancer | |||||
| Gallbladder Cancer | |||||
| Liver Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Bile Duct Neoplasms | |||||
| Gallbladder Neoplasms | |||||
| Liver Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Bile Duct Diseases | |||||
| Biliary Tract Diseases | |||||
| Biliary Tract Neoplasms | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gallbladder Diseases | |||||
| Liver Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| 4 | Interventions listed in this trial | ||||
| ixabepilone | |||||
| 5 | Sponsors listed in this trial | ||||
| University of Chicago | |||||
| National Cancer Institute (NCI) | |||||